

## Press Release

Lund, Sweden, September 22 2020

### ImmuneBiotech: Patent granted for GutMagnific® in the United States

ImmuneBiotech AB, the probiotic and microbiome company, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted a US patent protecting its probiotic product GutMagnific® in the USA. The patent US10.632,169B2 covers the composition of matter and use of GutMagnific®, this is an essential asset for ImmuneBiotech to become an emerging key player in the US – the largest market for probiotic dietary supplement.

GutMagnific® is a super-consortium (combination) of five probiotic lactobacillus strains, scientifically designed to address the underlying key causes of IBS and is sold as a food supplement [www.GutMagnific.com](http://www.GutMagnific.com). GutMagnific® is the first product in a new probiotic category ImmuneBiotics™ where products are developed using pharmaceutical precision focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier.

“I’m extremely pleased to have our first probiotic product GutMagnific® protected by a US patent confirming our outstanding innovation and representing a quality label for ImmuneBiotech. We are of course moving towards the US, the largest probiotic supplement market, with annual sales of USD 2 500 million. GutMagnific® has already gained attention from American consumers, business partners and even medical doctors. We are currently evaluating best strategies to enter the US market including an awarded Catalyst project by Business Sweden having their Chicago office engaged to find best strategies and partners”.

said Shahram Lavasani, CEO of ImmuneBiotech.

#### About GutMagnific® [www.GutMagnific.com](http://www.GutMagnific.com).

GutMagnific® is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of IBS. It is a patented combination of proprietary lactobacillus strains and is sold as a probiotic food supplement supported by clinical data. GutMagnific® has potential application in several severe and prevalent conditions such as IBS, diarrhea, antibiotic induced diarrhea, *Clostridium difficile* infection (CDI) and Chronic Fatigue Syndrome (ME/CFS). It has also the ability to target symptoms such as leaky gut and small intestine bacterial overgrowth (SIBO).

GutMagnific® is currently evaluated in a randomized, double blinded, placebo controlled, 3-arm clinical trial in Myalgic Encephalomyelitis (ME) also called Chronic Fatigue Syndrome (CFS) or post-viral fatigue. The trial is a collaboration with the ME/CFS clinic, Neurological Rehabilitation Clinic, Stora Sköndal, Stockholm, associated with Karolinska Institute, Stockholm, Sweden. As some 70% of ME/CFS patient also suffers from IBS, the hypothesis of the trial is that if the IBS can be ameliorated by GutMagnific® then the ME symptoms could also be improved.

## About ImmuneBiotech AB

ImmuneBiotech discovers and markets science-based probiotic food supplements. Based on our multi-disciplinary scientific foundation, we have created a new probiotic category ImmuneBiotics™ where products are developed using pharmaceutical precision focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier.

Shahram Lavasani, CEO

ImmuneBiotech Medical Sweden AB

s.lavasani@immunebiotech.com

+46 707 40 86 61

[www.ImmuneBiotech.com](http://www.ImmuneBiotech.com)



Dr. Shahram Lavasani, CEO ImmuneBiotech AB and inventor of GutMagnific® and Frida Björk, patent attorney at AWA discuss the requirements to obtain a patent and the innovation behind GutMagnific®. 4 min film in English, please use this link:

<https://onlineshares.immunebiotics.se/#share?id=0474b153-1ad5-4aa7-b5c1-242559aa2dc6>